

Chapman & Hall/CRC Biostatistics Series

# **Design and Analysis of Bridging Studies**

**Edited by**  
**Jen-pei Liu**  
**Shein-Chung Chow**  
**Chin-Fu Hsiao**



**CRC Press**

Taylor & Francis Group

Boca Raton London New York

---

CRC Press is an imprint of the  
Taylor & Francis Group, an **Informa** business

**A CHAPMAN & HALL BOOK**

---

# Contents

---

Preface.....	xv
Contributors.....	xvii
<b>1. Bridging Diversity: Extrapolating Foreign Data to a New Region .....</b>	<b>1</b>
<i>Shein-Chung Chow and Chin-Fu Hsiao</i>	
1.1 Introduction .....	1
1.2 Impact of Ethnic Differences .....	2
1.3 Regulatory Guidelines .....	4
1.3.1 ICH E5 Guideline on Bridging Studies.....	4
1.3.2 Regulatory Guidelines in Asia-Pacific Region.....	6
1.4 Current Issues.....	7
1.4.1 Criteria for Similarity .....	7
1.4.2 Sample Size Estimation and Allocation.....	8
1.5 Examples .....	10
1.6 Concluding Remarks .....	12
1.7 Aim and Structure of the Book .....	14
References .....	15
<b>2. Two-Stage Designs of Bridging Studies .....</b>	<b>17</b>
<i>Chin-Fu Hsiao, Hsiao-Hui Tsou, Jen-pei Liu, and Yuh-Jenn Wu</i>	
2.1 Introduction .....	17
2.2 Two-Stage Design for Bridging Studies .....	18
2.2.1 Two-Stage Design .....	19
2.2.2 Determining Sample Size and Critical Values .....	19
2.3 Group Sequential Approach to Evaluating Bridging Studies .....	25
2.3.1 Group Sequential Approach.....	25
2.3.2 Sample Size Determination .....	26
2.4 Concluding Remarks .....	30
References .....	31
<b>3. Consistency of Treatment Effects in Bridging Studies and Global Multiregional Trials .....</b>	<b>33</b>
<i>Weichung J. Shih and Hui Quan</i>	
3.1 Introduction .....	33
3.2 Global Clinical Trial.....	34
3.3 Consistency in Making Inference Regarding the Overall Treatment Effect $\theta$ .....	35
3.4 Consistency as a Method for Region-Specific Registration .....	39

3.5	Other Considerations .....	43
3.5.1	Time-to-Event and Binary Endpoints .....	43
3.5.2	Noninferiority Trial .....	44
3.5.3	MRCT Monitoring .....	44
3.6	Example .....	45
3.7	Discussion .....	46
	References .....	47
4.	<b>Assessing Similarity Using the Reproducibility and Generalizability Probabilities and the Sensitivity Index</b> .....	49
	<i>Shein-Chung Chow, Ying Lu, and Lan-Yan Yang</i>	
4.1	Introduction .....	49
4.2	Criteria for Assessing Similarity .....	50
4.3	Reproducibility and Generalizability .....	51
4.3.1	Test for Reproducibility .....	52
4.3.1.1	Estimated Power Approach .....	52
4.3.1.2	Confidence Bound Approach .....	56
4.3.1.3	Bayesian Approach .....	57
4.3.2	Evaluating the Generalizability Probability .....	63
4.4	Assessing the Similarity-Based Sensitivity Index .....	64
4.4.1	Population Shift between Regions .....	64
4.4.2	Case Where Both $\epsilon$ and $C$ Are Fixed .....	65
4.4.3	Case Where $\epsilon$ Is Random and $C$ Is Fixed .....	66
4.4.3.1	E-Step .....	67
4.4.3.2	M-Step .....	67
4.4.4	Case Where $\epsilon$ Is Fixed and $C$ Is Random .....	68
4.4.5	Case Where Both $\epsilon$ and $C$ Are Random .....	71
4.5	Concluding Remarks .....	75
	References .....	77
5.	<b>Combining Information in Clinical Drug Development: Bridging Studies and Beyond</b> .....	79
	<i>Kuang-Kuo Gordon Lan and José Pinheiro</i>	
5.1	Introduction .....	79
5.2	Leveraging Existing Information in Bridging Studies .....	80
5.2.1	Weighted Z-Test Approach .....	81
5.2.2	Discount Factor Approach .....	83
5.3	Application: Bridging of Blood Pressure Drug .....	84
5.4	Discussion .....	85
	References .....	87
6.	<b>A Bayesian Approach for Evaluation of Bridging Studies</b> .....	89
	<i>Chin-Fu Hsiao, Hsiao-Hui Tsou, Jen-pei Liu, and Yuh-Jenn Wu</i>	
6.1	Introduction .....	89

6.2	Mixture of Prior Information .....	91
6.3	Determination of Sample Size.....	94
6.4	Examples .....	97
6.5	Concluding Remarks .....	102
	References .....	104
<b>7.</b>	<b>Issues of Sample Size in Bridging Trials and Global Clinical Trials.....</b>	<b>105</b>
	<i>Hsien-Ming James Hung, Sue-Jane Wang, and Robert O'Neill</i>	
7.1	Issues of Sample Size Planning for Bridging Trial.....	105
7.2	Issues of Sample Size Planning in Global Clinical Trial .....	108
7.3	Impacts of Consistency Assessment on Sample Size.....	112
7.4	Discussion .....	117
	References .....	118
<b>8.</b>	<b>Design and Sample Size Considerations for Global Trials .....</b>	<b>121</b>
	<i>Christy Chuang-Stein, Yoichi Ii, Norisuke Kawai, Osamu Komiyama, and Kazuhiko Kuribayashi</i>	
8.1	Introduction .....	121
8.2	Points to Consider When Designing a Multiregional Trial .....	126
8.2.1	Clinical Considerations.....	126
8.2.2	Statistical Considerations.....	127
8.2.3	Regulatory Considerations.....	128
8.2.4	Commercial Considerations.....	128
8.2.5	Operational Considerations .....	129
8.3	Determination of Regional Sample Size in a Multiregional Study.....	130
8.3.1	Assumption That Treatment Effect Is Uniform across Regions.....	131
8.3.2	Variation in True Treatment Effect across Regions.....	134
8.3.3	Consistency Range for Sample Sizing .....	139
8.3.4	Other Approaches.....	140
8.4	Additional Analysis to Estimate Treatment Effects in Different Regions .....	141
8.4.1	Notations.....	142
8.4.2	Estimation of Regional Effect Size .....	143
8.5	Real-Time Monitoring of Multiregional Trials .....	144
8.6	Concluding Remarks .....	146
	References .....	148
<b>9.</b>	<b>Application of Genomic Technologies for Bridging Strategy Involving Different Race and Ethnicity in Pharmacogenomics Clinical Trials.....</b>	<b>151</b>
	<i>Sue-Jane Wang</i>	
9.1	Introduction .....	151

9.2	Pharmacogenomics and Pharmacogenetics.....	153
9.2.1	Definition .....	153
9.2.2	Genomic (Composite) Biomarker.....	154
9.2.3	Clinical Utility .....	154
9.2.3.1	Prognostic.....	155
9.2.3.2	Predictive.....	156
9.2.3.3	Prognostic and Predictive.....	156
9.2.4	Assessment of Clinical Utility and Therapeutic Effect .....	156
9.3	Bridging .....	158
9.3.1	New Region Trial—External Bridging Strategy .....	158
9.3.1.1	External Bridging Strategy .....	159
9.3.1.2	NSCLC Patient Composition in Regional Pharmacogenomics Trials.....	160
9.3.1.3	Results Observed in Regional Pharmacogenomics Trials.....	161
9.3.1.4	Consistent Observation between OTR and PFS in EGFR+ NSCLC Patient Subset.....	163
9.3.1.5	Inconsistent Observation of OS in EGFR+ NSCLC Patient Subset .....	163
9.3.2	Original Region Trial—Internal Bridging Strategy .....	164
9.3.2.1	Internal Bridging Strategy .....	164
9.3.2.2	Potential Genomics Factors Explored.....	165
9.3.2.3	Absence of Patients from East Asia .....	165
9.4	Bridging Study Evaluation.....	166
9.4.1	Treatment Effect Demonstrated in Original Region.....	166
9.4.1.1	Indirect Evaluation of Bridging Effect .....	167
9.4.1.2	Type I Error Assessment .....	168
9.4.1.3	Direct Evaluation.....	169
9.4.1.4	Comparisons of Methods.....	169
9.4.2	Treatment Effect Not Demonstrated in Original Region.....	170
9.4.3	Internal Bridging Strategy in Multiregional Clinical Trial .....	171
9.4.3.1	Blinded Two-Stage Adaptive Test .....	171
9.4.3.2	Unblinded Two-Stage Adaptive Test.....	172
9.5	Challenges of Bridging Strategy in Pharmacogenomics.....	174
9.5.1	Prospective–Retrospective Design and Analysis .....	174
9.5.1.1	Probability of Observed Imbalance with Small Sample Size .....	175
9.5.1.2	Close to Full Ascertainment of Genomic Samples in Pharmacogenomics Trials.....	176

9.5.2	Genomic Convenience Samples.....	177
9.5.2.1	Baseline Imbalance .....	178
9.5.2.2	Inferential Problems .....	179
9.5.3	Genomics <i>In Vitro</i> Diagnostics.....	182
9.5.3.1	Impact of Misclassification of an IVD in Pharmacogenomics Clinical Trial.....	183
9.5.4	Region as a Confounder to Ethnic Sensitivity .....	184
9.5.5	Implication of Futility Analysis with an Unblinded Adaptive Test in MRCT.....	185
9.5.6	Other Complex Issues .....	186
9.5.7	Replication Issue .....	187
9.6	Concluding Remarks .....	189
	References .....	190
<b>10.</b>	<b>Interaction Effects in Bridging Studies .....</b>	<b>197</b>
	<i>Eric Tsung-Cheng Hsieh and Jen-pei Liu</i>	
10.1	Introduction .....	197
10.2	Noninferiority Hypothesis for Treatment Similarity .....	199
10.3	Statistical Testing Procedures .....	200
10.4	Simulation Studies .....	205
10.5	Numerical Examples .....	209
10.5.1	Applications to Evaluation of Bridging Studies .....	209
10.5.2	Application to Evaluation of Age Groups within the Same Study .....	213
10.6	Discussion and Final Remarks.....	214
	References .....	217
<b>11.</b>	<b>Multiregional Clinical Trials.....</b>	<b>219</b>
	<i>Yi Tsong and Hsiao-Hui Tsou</i>	
11.1	Introduction .....	219
11.2	Different Regional Requirements.....	220
11.2.1	Different Noninferiority Margins.....	221
11.2.2	Different Time Points Requirements .....	221
11.2.3	Different Experimental Designs.....	222
11.2.4	Different Endpoints Required by Two Regions .....	223
11.2.4.1	Two Subset Testing.....	224
11.2.4.2	Testing Two Sequential Overall Hypotheses Using All Sample Size .....	224
11.2.4.3	Testing Two Parallel Overall Hypotheses with No Adjustment .....	225
11.2.4.4	Testing Two Parallel Overall Hypotheses with Type I Error Rate Adjustment .....	225
11.3	Bridging the Overall Treatment Effect to Regions .....	225
11.4	Summary.....	232
	References .....	232

<b>12. Multiregional Clinical Trials for Global Simultaneous Drug Development in Japan .....</b>	<b>235</b>
<i>Kihito Takahashi, Mari Ikuta, and Hiromu Nakajima</i>	
12.1 Introduction .....	235
12.2 Drug Lag.....	236
12.3 MRCTs as a Solution to Drug Lag.....	236
12.4 Improvements in Clinical Trial Environment in Japan .....	237
12.5 Growing Trends of MRCTs in Japan .....	238
12.5.1 Trends in CTN and PMDA Clinical Trial Consultations on MRCTs .....	238
12.5.2 Industry Surveys.....	238
12.6 MRCTs in the Field of Oncology .....	239
12.6.1 Necessity of MRCTs in the Field of Oncology .....	239
12.6.2 PMDA Consultation on MRCTs in the Field of Anticancer Drugs.....	240
12.6.3 Ethnic or Regional Differences .....	240
12.6.4 Differences in Clinical Staging and Medical Environment.....	241
12.6.5 New Paradigm.....	241
12.7 MRCTs in the Field of CVM .....	242
12.7.1 Necessity of MRCTs in the Field of Oncology .....	242
12.7.2 Ethnic Factors .....	242
12.7.3 Intrinsic Factors.....	243
12.7.4 Extrinsic Factors.....	244
12.7.5 Key Determinants for Successful MRCTs in CVM Field .....	244
12.8 Issues in MRCTs.....	245
12.8.1 Ethnic Factors .....	245
12.8.2 Regulatory Requirements.....	245
12.8.3 Operational Issues .....	246
12.9 Future Prospects .....	246
References .....	247
 <b>13. Feasibility and Implementation of Bridging Studies in Taiwan .....</b>	<b>251</b>
<i>Mey Wang, Yeong-Liang Lin, and Heng-Der Chern</i>	
13.1 Overview .....	251
13.2 Regulatory History of Bridging Strategy .....	252
13.3 Assessment Experiences Based on ICH E5 .....	254
13.3.1 Case 1.....	255
13.3.2 Case 2.....	256
13.4 Bayesian Statistical Approach to Bridging Studies .....	257
13.4.1 Evaluating Regional Treatment Effect in a Multiregional Trial.....	257

13.4.2 Regional Power and Sample Size Allocation in a  
Multiregional Trial..... 259

13.5 Designing an External (Supplemental) Bridging Study..... 260

13.6 Concluding Remarks..... 261

References ..... 262

**Index ..... 265**